• Cy3 Maleimide: Identity, Mechanism, and Evidence

  2026-10-16

  Cy3 maleimide (non-sulfonated) is described by APExBIO as a thiol-reactive Cy3 fluorophore for covalent labeling of cysteine residues and other thiol-containing molecules. The product information supports a conceptual account of maleimide–thiol conjugation and fluorescence readout, but it does not provide identity-matched research evidence, independent performance measurements, comparative data, or study-specific outcomes.

• DiscoveryProbe FDA-approved Drug Library: Evidence Scope

  2026-10-16

  The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021), supplied by APExBIO, is described as a 2,320-compound collection of clinically approved or pharmacopeia-listed bioactive molecules spanning several pharmacological classes. Its documented value is organizational and screening-oriented: it brings compounds with diverse reported mechanisms into a common collection. The available product information does not provide an identity-matched research study, assay outcomes, effect sizes, comparators, or independent validation of screening performance. Accordingly, the library’s intended roles in drug repositioning screening and pharmacological target identification should not be treated as demonstrated findings.

• Protease Inhibitor Cocktail: Evidence Boundaries

  2026-10-15

  The APExBIO Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) is documented as a multi-inhibitor formulation intended to limit endogenous proteolysis during protein extraction and sample preparation. Its named ingredients and EDTA-free formulation support a plausible class-level mechanism, but the available information contains no identity-matched research paper, quantitative performance data, or direct comparator study. Product claims should therefore be separated from evidence about assay-specific preservation, native structure, phosphorylation, or functional activity.

• Estradiol Benzoate: What the Product Record Supports

  2026-10-15

  APExBIO describes Estradiol Benzoate as a synthetic estradiol analog and estrogen receptor alpha agonist for research use. The product record reports ERα-associated IC50 values of 22–28 nM across human, murine, and chicken models, but provides no identity-matched paper, assay details, independent replication, or downstream signaling results. Those limitations restrict interpretation to a documented product identity and supplier-reported receptor-interaction claim.

• Doxycycline: Product Identity and Evidence Boundaries

  2026-10-14

  The APExBIO product page identifies Doxycycline as a tetracycline antibiotic and describes antimicrobial, metalloproteinase-inhibitory, and antiproliferative activities. Because no identity-matched research paper is available with the product information, these statements should be treated as supplier-documented claims rather than quantified evidence of mechanism, potency, selectivity, or clinical effect.

• HOXC9, Apoptosis, and ESCC Evidence

  2026-10-14

  A source-grounded overview of evidence linking HOXC9 to ESCC proliferation and mitochondria-associated apoptosis, with attention to how Annexin V/PI measurements can inform—but cannot by themselves establish—this mechanism.

• Saracatinib and the Reelin–SFK Ketamine Study

  2026-10-13

  The PNAS study supports a permissive role for Reelin–ApoER2–SFK signaling in ketamine-related synaptic and behavioral effects in mice. It does not establish that Saracatinib (AZD0530) was used in that work, nor that its oncology-oriented Src/Abl profile predicts antidepressant activity.

• Ionic Liquids and Coil–Bottlebrush Network Phases

  2026-10-13

  Rodriguez, Mahanthappa, and Lodge examine whether coil-selective ionic liquids can broaden access to three-dimensional network morphologies in coil–bottlebrush diblock copolymers. Their reported phase behavior varies only weakly across the ionic-liquid series, but the evidence remains bounded by the tested polymer architecture, composition, and solvent family.

• Mdivi-1 Evidence in Hypoxic Pulmonary Hypertension

  2026-10-12

  A 2025 study links endothelial ADAM10 signaling with DRP1- and PI3K-related changes in smooth muscle cells under hypoxia. Its use of Mdivi-1 supports a mechanistic association, but does not establish target selectivity, pathway order, comparative efficacy, or clinical benefit.

• saRNA Influenza Vaccines: Findings and Boundaries

  2026-10-12

  The supplied 2026 study reports stronger and more durable immune responses for a self-amplifying RNA influenza vaccine than for conventional mRNA in mouse models, particularly against influenza B. The findings are promising but remain preclinical, formulation-specific, and insufficient to establish human effectiveness or safety. DNase I (RNase-free) is discussed separately as a DNA-cleaving reagent; the cited vaccine study does not document its use.

• Doxycycline Nanomedicine for AAA: Evidence and Limits

  2026-10-11

  A 2025 preclinical study reports that cRGD-functionalized tea polyphenol nanoparticles can improve lesion-associated delivery of doxycycline in abdominal aortic aneurysm models. The findings are promising but remain preliminary: they do not establish clinical efficacy, long-term safety, or applicability to human aneurysm management.

• Shufeng Xingbi Therapy, Gut Flora, and AR

  2026-10-10

  A 2025 bioRxiv preprint examines how Shufeng Xingbi Therapy may improve ovalbumin-associated allergic rhinitis in rats through coordinated changes in nasal inflammatory signaling, serum mediators, short-chain fatty acids, and intestinal microbial composition. Its main contribution is an integrated microbiome–immune framework, although the findings remain preliminary because the study was not peer reviewed and used a small animal cohort.

• S-Adenosylmethionine: From Cofactor to Strategy

  2026-10-09

  Ademetionine is more than a methyl donor: it is a strategic lens for understanding substrate selectivity, pathway control, and translational assay design. New findings on the mulberry methyltransferase MaMT4 show why SAM-dependent biology must be interpreted through enzyme context, not cofactor availability alone.

• Batimastat (BB-94): MMP Evidence Across Biology

  2026-10-09

  Batimastat (BB-94) is a broad-spectrum matrix metalloproteinase inhibitor with established preclinical relevance in cancer research, but its relationship to neuromuscular-junction development remains a research question rather than a demonstrated application. The strongest supplied evidence concerns muscle-derived BDNF, its localized release, and proteolytic processing—not direct testing of Batimastat in the reported synaptic models.

• TRIM21–ERK1/2 Signaling in Pituitary Adenomas

  2026-10-08

  A 2025 Neuro-Oncology study identifies TRIM21 as an E3 ligase that connects K27-linked ubiquitination of ERK1/2 with phosphorylation, pituitary adenoma proliferation, and dopamine-agonist resistance. Its drug-screening results nominate Quisinostat and Fimepinostat as research candidates for reducing TRIM21, but the findings remain preclinical and require independent validation.

8077 records 1/539 page Next 12345 下5页 Last page